Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/58991
Type
ArticleCopyright
Open access
Collections
- ENSP - Artigos de Periódicos [2212]
- INI - Artigos de Periódicos [3186]
- IOC - Artigos de Periódicos [12341]
Metadata
Show full item record
INFLAMMASOME GENES POLYMORPHISMS ARE ASSOCIATED WITH PROGRESSION TO MECHANICAL VENTILATION AND DEATH IN A COHORT OF HOSPITALIZED COVID-19 PATIENTS IN A REFERENCE HOSPITAL IN RIO DE JANEIRO, BRAZIL
The study protocol was approved by the Ethics Committee of the National Institute of Infectology Evandro Chagas (INI)/Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil, under approval number CAAE: 32449420.4.1001.5262. All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national).
Author
Neira-Goulart, Milena
Sá, Nathalia Beatriz Ramos de
Ribeiro-Alves, Marcelo
Perazzo, Hugo
Geraldo, Kim Mattos
Ribeiro, Maria Pia Diniz
Cardoso, Sandra Wagner
Grinsztejn, Beatriz
Veloso, Valdiléa G.
Gomes, Larissa Rodrigues
Cazote, Andressa da Silva
Almeida, Dalziza Victalina de
Giacoia-Gripp, Carmem Beatriz Wagner
Côrtes, Fernanda Heloise
Morgado, Mariza Gonçalves
Sá, Nathalia Beatriz Ramos de
Ribeiro-Alves, Marcelo
Perazzo, Hugo
Geraldo, Kim Mattos
Ribeiro, Maria Pia Diniz
Cardoso, Sandra Wagner
Grinsztejn, Beatriz
Veloso, Valdiléa G.
Gomes, Larissa Rodrigues
Cazote, Andressa da Silva
Almeida, Dalziza Victalina de
Giacoia-Gripp, Carmem Beatriz Wagner
Côrtes, Fernanda Heloise
Morgado, Mariza Gonçalves
Affilliation
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Center of Technological Development in Health. National Institute of Science and Technological for Innovation on Neglected Population Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. National Institute of Infectology Evandro Chagas. Laboratory of Clinical Research on STD/AIDS. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Center of Technological Development in Health. National Institute of Science and Technological for Innovation on Neglected Population Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of AIDS & Molecular Immunolog. Rio de Janeiro, RJ, Brazil.
Abstract
COVID-19 has a broad spectrum of clinical manifestations. We assessed the impact of single nucleotide polymorphisms (SNPs) of inflammasome genesas risk factors for progression toCOVID-19 critical outcomes, such as mechanical ventilation support (MVS) or death.The study included 451 hospitalized individuals followed up at the INI/FIOCRUZ, Rio de Janeiro, Brazil, from 06/2020 to 03/2021. SNPs genotyping was determined by Real-Time PCR. We analyzed risk factors for progression to MVS (n = 174[38.6 %]) or death (n = 175[38.8 %])as a result of COVID-19 by Cox proportional hazardmodels.Slower progression toMVSwas associated with allele G (aHR = 0.66;P = 0.005) or the genotype G/G (aHR = 0.391;P = 0.006) in the NLRP3 rs10754558 or the allele G (aHR = 0.309;P = 0.004) in the IL1βrs1143634, while C allele in the NLRP3 rs4612666 (aHR = 2.342;P = 0.006) or in the rs10754558 (aHR = 2.957;P = 0.005) were associated with faster progression to death. Slower progression to death was associated to allele G (aHR = 0.563;P = 0.006) or the genotype A/G (aHR = 0.537;P = 0.005) in the CARD8 rs6509365; the genotype A/C in the IFI16 rs1101996 (aHR = 0.569;P = 0.011); the genotype T/T (aHR = 0.394;P = 0.004) or allele T (aHR = 0.68;P = 0.006) in the NLRP3 rs4612666, and the genotype G/G (aHR = 0.326;P = 0.005) or allele G (aHR = 0,68;P = 0.014) in the NLRP3 rs10754558. Our results suggest that inflammasome genetic variations might influence the critical clinical course of COVID-19.
Publisher
Elsevier
Citation
NEIRA-GOULART, Milena et al. Inflammasome genes polymorphisms are associated with progression to mechanical ventilation and death in a cohort of hospitalized COVID-19 patients in a reference hospital in Rio de Janeiro, Brazil. Gene, p. 1-11, May 2023.DOI
10.1016/j.gene.2023.147325ISSN
0378-1119Notes
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.The study protocol was approved by the Ethics Committee of the National Institute of Infectology Evandro Chagas (INI)/Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil, under approval number CAAE: 32449420.4.1001.5262. All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national).
Share